IL86499A - Heterocyclic compounds substituted with aralkyl, their preparation and pharmaceutical compositions containing them - Google Patents

Heterocyclic compounds substituted with aralkyl, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL86499A
IL86499A IL86499A IL8649988A IL86499A IL 86499 A IL86499 A IL 86499A IL 86499 A IL86499 A IL 86499A IL 8649988 A IL8649988 A IL 8649988A IL 86499 A IL86499 A IL 86499A
Authority
IL
Israel
Prior art keywords
radical
cyano
hydroxy
alkyl
alkoxy
Prior art date
Application number
IL86499A
Other languages
English (en)
Other versions
IL86499A0 (en
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10618970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL86499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of IL86499A0 publication Critical patent/IL86499A0/xx
Publication of IL86499A publication Critical patent/IL86499A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL86499A 1987-06-16 1988-05-25 Heterocyclic compounds substituted with aralkyl, their preparation and pharmaceutical compositions containing them IL86499A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878714013A GB8714013D0 (en) 1987-06-16 1987-06-16 (substituted-aralkyl)heterocyclic compounds

Publications (2)

Publication Number Publication Date
IL86499A0 IL86499A0 (en) 1988-11-15
IL86499A true IL86499A (en) 1997-09-30

Family

ID=10618970

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86499A IL86499A (en) 1987-06-16 1988-05-25 Heterocyclic compounds substituted with aralkyl, their preparation and pharmaceutical compositions containing them

Country Status (22)

Country Link
US (2) US4935437A (fr)
EP (1) EP0296749B1 (fr)
JP (1) JP2609290B2 (fr)
AT (1) ATE113277T1 (fr)
AU (1) AU605872B2 (fr)
CA (1) CA1337420C (fr)
DE (1) DE3851914T2 (fr)
DK (1) DK174573B1 (fr)
ES (1) ES2063036T3 (fr)
FI (1) FI97804C (fr)
GB (1) GB8714013D0 (fr)
HK (1) HK1000206A1 (fr)
HU (1) HU211142A9 (fr)
IE (1) IE65570B1 (fr)
IL (1) IL86499A (fr)
LU (1) LU88778I2 (fr)
MX (1) MX9202876A (fr)
NL (1) NL970012I2 (fr)
NO (2) NO170080C (fr)
NZ (1) NZ225037A (fr)
PT (1) PT87720B (fr)
ZA (1) ZA883691B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
NZ236440A (en) * 1989-12-15 1993-07-27 Merck & Co Inc Reversal of sexual phenotype in poultry using an inhibitor of steroid biotransformation and/or aromatase inhibitor, poultry produced by this process
EP0445073A1 (fr) * 1990-02-27 1991-09-04 Ciba-Geigy Ag Benzofurannes
EP0457716A1 (fr) * 1990-04-20 1991-11-21 Ciba-Geigy Ag Dérivés de naphtaline
TW224461B (fr) * 1990-09-18 1994-06-01 Ciba Geigy Ag
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
KR100219760B1 (ko) * 1996-03-13 1999-09-01 김성환 보온 단열재
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
WO2005105762A1 (fr) * 2004-05-05 2005-11-10 Natco Pharma Limited Procede ameliore pour la preparation d'une anastrozole a purete elevee
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0414120D0 (en) * 2004-06-24 2004-07-28 Generics Uk Ltd Novel processes and intermediates
US20060035950A1 (en) * 2004-08-09 2006-02-16 Mohammed Alnabari Novel processes for preparing substantially pure anastrozole
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
US20060189670A1 (en) * 2005-02-22 2006-08-24 Glenmark Pharmaceuticals Limited Process for the preparation of anastrozole and intermediates thereof
EP1705168A1 (fr) * 2005-03-21 2006-09-27 Helm AG Procédé amelioré de bromuration d'alkylbenzènes dans la chaine laterale
EP1751121A2 (fr) * 2005-04-06 2007-02-14 Sicor Inc. Procede de preparation de l'anastrozole
WO2007002722A2 (fr) * 2005-06-27 2007-01-04 Sicor, Inc. Procédé de purification d'un intermédiaire de l'anastrozole
US20070032660A1 (en) * 2005-06-27 2007-02-08 Alessandro Pontiroli Purification process for Anastrozole intermediate
EP1940806A2 (fr) * 2005-09-30 2008-07-09 Cadila Healthcare Ltd. Procede de preparation d'anastrozole pur
WO2007039913A1 (fr) * 2005-10-05 2007-04-12 Usv Limited Procede de preparation de 2,2'-[5-(1,2,4-triazole-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile).
WO2007039919A1 (fr) * 2005-10-06 2007-04-12 Natco Pharma Limited Formes cristallines d'anastrozole
US20070100148A1 (en) * 2005-10-31 2007-05-03 Veerender Murki Process for preparing anastrozole
US20090286989A1 (en) * 2006-03-10 2009-11-19 Vishnukant B Process for High Purity Anastrozole
EP2024343B1 (fr) * 2006-05-19 2015-09-09 Synthon B.V. Procédé de purification de l'anastrozole
EP2029557A1 (fr) * 2006-06-05 2009-03-04 Cadila Healthcare Ltd. Procédé de préparation d'anastrozole pur
WO2008034644A2 (fr) * 2006-09-22 2008-03-27 Synthon B.V. Procédé de fabrication d'anastrozole
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP2066646B1 (fr) * 2006-10-17 2012-06-13 Cipla Limited Procédé d'élaboration d'anastrozole pur
US20080177081A1 (en) * 2007-01-19 2008-07-24 Formosa Laboratories, Inc. Process for Preparation of Anastrozole
CN101307027B (zh) * 2007-05-17 2011-09-07 杜焕达 一种阿那曲唑的新的制备方法
WO2009018811A1 (fr) * 2007-08-06 2009-02-12 Schebo Biotech Ag Nouveaux médicaments, procédé pour leur production et leur utilisation thérapeutique médicale
JP5558358B2 (ja) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド メタボリック症候群用のtrans−クロミフェン
WO2009128919A1 (fr) * 2008-04-15 2009-10-22 Concert Pharmaceuticals, Inc. Analogues d'anastrozole portant du deutérium en tant qu'inhibiteurs d'aromatase pour le traitement du cancer du sein
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
DE102010046464A1 (de) 2009-03-19 2011-04-21 Amw Gmbh Transdermales System mit Aromatasehemmer
EP2343278A1 (fr) 2010-01-07 2011-07-13 Hexal AG Procédé de préparation de dérivés de phényle trisubstitué comprenant un groupe (1H-1,2,4-triazol-1-yl)alkyle
DE102010026883A1 (de) 2010-03-11 2011-12-15 Amw Gmbh Transdermales System mit Aromatasehemmer
CA2865234A1 (fr) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Polytherapie pour le traitement d'une carence en androgene
CN103172580B (zh) * 2013-03-29 2015-04-22 凯莱英医药集团(天津)股份有限公司 一种阿那曲唑的制备方法
ITRM20130285A1 (it) 2013-05-14 2014-11-15 Corden Pharma Latina S P A Con Uni Co Socio Metodo per la preparazione di anastrozolo di grado farmaceutico
CN103342663B (zh) * 2013-07-15 2015-07-29 凯莱英医药集团(天津)股份有限公司 一种阿那曲唑关键中间体的制备方法
CN104387332B (zh) * 2014-11-27 2016-04-13 江苏正大清江制药有限公司 一种合成芳香化酶抑制剂的方法
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
CN106083748B (zh) * 2016-06-21 2019-08-16 扬子江药业集团江苏海慈生物药业有限公司 一种阿那曲唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431407C2 (de) * 1974-06-29 1982-12-02 Bayer Ag, 5090 Leverkusen 1,2,4-Triazol-1-yl-alkanone und -alkanole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Fungizide
JPS55313A (en) * 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
CA1134828A (fr) * 1978-12-28 1982-11-02 Tadao Tanouchi Derives de la pyridine
ZA84652B (en) * 1983-02-02 1985-09-25 Lilly Co Eli Aromatase inhibiting pyrimidine derivatives
US4801594A (en) * 1984-06-18 1989-01-31 Eli Lilly And Company Aromatase inhibitors
US4755526A (en) * 1984-06-18 1988-07-05 Eli Lilly And Company Method of inhibiting aromatase
US4766140A (en) * 1984-06-18 1988-08-23 Eli Lilly And Company Method of inhibiting aromatase
GB2162513B (en) * 1984-06-25 1988-01-20 Toyama Chemical Co Ltd Dihydropyridine derivatives
US4699652A (en) * 1985-07-22 1987-10-13 Hoffmann-La Roche Inc. Fungicidal pyridine derivatives for use in agriculture
EP0228995A1 (fr) * 1985-12-20 1987-07-15 Ciba-Geigy Ag Microbicides
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
EP0275955B1 (fr) * 1987-01-21 1990-07-04 Ciba-Geigy Ag Composition microbicide

Also Published As

Publication number Publication date
MX9202876A (es) 1992-06-30
ES2063036T3 (es) 1995-01-01
US4935437A (en) 1990-06-19
EP0296749A1 (fr) 1988-12-28
FI97804C (fi) 1997-02-25
ATE113277T1 (de) 1994-11-15
DE3851914D1 (de) 1994-12-01
DK330488D0 (da) 1988-06-16
NL970012I2 (nl) 1997-07-01
GB8714013D0 (en) 1987-07-22
NO170080B (no) 1992-06-01
USRE36617E (en) 2000-03-14
NO1997006I1 (no) 1997-05-16
PT87720A (pt) 1988-07-01
AU605872B2 (en) 1991-01-24
AU1691188A (en) 1988-12-22
HU211142A9 (en) 1995-10-30
FI97804B (fi) 1996-11-15
NO170080C (no) 1992-09-09
PT87720B (pt) 1992-10-30
LU88778I2 (fr) 1996-11-05
CA1337420C (fr) 1995-10-24
JP2609290B2 (ja) 1997-05-14
HK1000206A1 (en) 1998-02-06
NO882628L (no) 1988-12-19
IL86499A0 (en) 1988-11-15
NZ225037A (en) 1991-10-25
IE65570B1 (en) 1995-11-01
IE881505L (en) 1988-12-16
DE3851914T2 (de) 1995-03-23
ZA883691B (en) 1989-02-22
DK174573B1 (da) 2003-06-23
EP0296749B1 (fr) 1994-10-26
JPS6419067A (en) 1989-01-23
FI882882A (fi) 1988-12-17
FI882882A0 (fi) 1988-06-16
NO882628D0 (no) 1988-06-15
DK330488A (da) 1988-12-17
NL970012I1 (nl) 1997-05-01

Similar Documents

Publication Publication Date Title
IL86499A (en) Heterocyclic compounds substituted with aralkyl, their preparation and pharmaceutical compositions containing them
KR900004333A (ko) 맥관 형성 억제제
KR920701167A (ko) 약제학적 활성 화합물
AU6307290A (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
KR900003157A (ko) 트리아졸 항진균제
EP0299683A3 (fr) Composés oléfinique hétérocycliques et leur utilisation comme inhibiteurs d'aromatase
NZ223752A (en) Triazole and imidazole derivatives and pharmaceutical compositions
IE821721L (en) Imidazole derivatives
KR950032178A (ko) 치환된 피라졸린 유도체
NZ220703A (en) Triazole and imidazole derivatives and pharmaceutical compositions
HU185802B (en) Process for producing 1,2,4-triazine derivatives
AU8372791A (en) 1,3-dioxan-5-yl alkenoic acids, processes of preparation and pharmaceutical compositions containing them
CA2542361A1 (fr) Derive d'azole utiles en tant qu'agents antifongiques, ayant une interaction limitee avec les cytochromes metaboliques
KR870004979A (ko) 할로알콕시 치환된 2-(1h-1,2,4-트리아졸릴)-1-페닐에탄-1-온 케탈을 함유하는 살균제
KR840008801A (ko) 아졸 유도체의 제조방법
KR930010033A (ko) 광학적 활성 아졸 화합물, 그의 제조방법 및 용도

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired